Pharmaceutical Executive: February 2023

Their integration across enterprise remains pivotal driver for success.

Branding agency experts share what to know when it comes to legal, regulatory, and creative approaches in the complex drug-naming process, with its potential to shape a campaign’s success.

A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.

Health disparities brought on by racial bias remain quite prevalent in areas such as drug access, use of diagnostics, and representation in clinical trials, but society-jarring events in recent years have sparked renewed efforts by industry to tackle these issues with tangible and hopeful gains.

Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.

Starting out with limited pharma business knowledge, how the lessons learned and realizations made helped to forge a destined—and globe-spanning—leadership path for Christophe Bourdon, where today, as CEO of LEO Pharma, he is tasked with steering the longtime company’s return to profitability.

Chronicling the market’s rise and fall—and signs of potential recovery.

Biopharma insiders believe it’s time to invest in technology again.

Examining efforts to boost women representation on company boards.

Is agenda blurring the line between alliances and assimilation?

Probe targets agency’s role in advising on drug testing and submissions.

Pharm Exec's February issue focuses on health equity.